Plato Investment Management Ltd Has $18.28 Million Position in Johnson & Johnson $JNJ

Plato Investment Management Ltd boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 3.9% during the second quarter, Holdings Channel reports. The fund owned 72,416 shares of the company’s stock after purchasing an additional 2,743 shares during the period. Johnson & Johnson makes up 1.0% of Plato Investment Management Ltd’s holdings, making the stock its 14th largest holding. Plato Investment Management Ltd’s holdings in Johnson & Johnson were worth $18,284,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in JNJ. Auto Owners Insurance Co raised its position in shares of Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter valued at about $6,924,523,000. Capital World Investors acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $2,005,942,000. Diamant Asset Management Inc. boosted its holdings in shares of Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after acquiring an additional 4,454,778 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Johnson & Johnson by 41.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company’s stock valued at $2,571,124,000 after purchasing an additional 3,655,754 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved J&J’s oral psoriasis pill, Icotyde, expanding the company’s immunology portfolio and giving it a simpler treatment option to compete with rival products from Bristol Myers Squibb and AbbVie. The pill could also broaden J&J’s presence in China, although it may compete with the company’s established injectable Tremfya franchise. China approves J&J’s oral psoriasis pill
• Positive Sentiment: The FDA expanded approval of Imaavy for warm autoimmune hemolytic anemia in patients 12 and older who are receiving or have previously received steroids. As the first approved treatment for this rare, potentially life-threatening disorder, Imaavy addresses an unmet need and could support J&J’s rare-disease growth strategy. Imaavy expands into rare blood disorder
• Positive Sentiment: Recent analysis points to a favorable shift in J&J’s product mix, with newer products increasingly offsetting pressure from the STELARA patent loss. This supports the view that growth in the broader Innovative Medicine portfolio may be more important than the shrinking contribution from STELARA. Did a product swap fuel JNJ stock’s surge?
• Positive Sentiment: Investors continue to view JNJ as a defensive dividend holding, supported by its balance sheet, diversified healthcare operations and ability to generate dependable returns through economic cycles. Johnson & Johnson is a top dividend stock

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Morgan Stanley raised their price target on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Scotiabank reissued an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Johnson Rice reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, Royal Bank Of Canada boosted their price target on Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $268.22.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 63,972 shares of company stock worth $16,245,605 in the last 90 days. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

JNJ stock opened at $268.30 on Friday. The company has a 50 day simple moving average of $258.88 and a 200 day simple moving average of $243.94. The stock has a market cap of $646.58 billion, a price-to-earnings ratio of 31.09, a P/E/G ratio of 2.56 and a beta of 0.24. Johnson & Johnson has a 1 year low of $173.33 and a 1 year high of $276.47. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s payout ratio is currently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.